How are weight-loss drugs shaping the future of the supplement industry?
From GLP-1 drugs' role in lowering the national obesity rate to social media’s spotlight on Berberine, we're experiencing seismic shifts in the weight loss and blood sugar management markets.
In the Supplements in the Ozempic Age Report, NBJ analyzes these influences and reveals what they mean for supplement brands today and in the years to come.
This special report features:
Consumer Research: What consumers want and need in nutrition before, during and after GLP-1 drugs.
Signature NBJ Data: Sales and growth data for Weight Management and Blood Sugar Management with estimates through 2027.
Prepare for the future of weight loss supplements with expert insights, actionable data, and clear strategies to thrive in this evolving landscape with the Supplements in the Ozempic Age Report.
This email was sent to you by the Informa Markets Division of Informa PLC (Privacy Policy). Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
If you do not wish to receive further information from us, please click here. Alternatively, to contact our data services team to have your details or preferences updated please email imdatateam@informa.com.
